DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Harbeck N, Im S-A, Barrios CH. et al.
Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC).
J Clin Oncol 2020;
38: 500-500
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.